Point72 DIFC Ltd Buys New Shares in Repligen Co. (NASDAQ:RGEN)

Point72 DIFC Ltd bought a new position in shares of Repligen Co. (NASDAQ:RGEN) during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor bought 21,686 shares of the biotechnology company’s stock, valued at approximately $3,227,000.

A number of other hedge funds and other institutional investors also recently modified their holdings of the company. Champlain Investment Partners LLC increased its position in Repligen by 149.0% during the third quarter. Champlain Investment Partners LLC now owns 1,420,935 shares of the biotechnology company’s stock worth $211,464,000 after buying an additional 850,345 shares during the last quarter. Bank of New York Mellon Corp boosted its stake in shares of Repligen by 21.0% during the 2nd quarter. Bank of New York Mellon Corp now owns 1,370,375 shares of the biotechnology company’s stock worth $172,749,000 after acquiring an additional 237,884 shares during the period. Conestoga Capital Advisors LLC increased its holdings in shares of Repligen by 26.7% during the 2nd quarter. Conestoga Capital Advisors LLC now owns 946,877 shares of the biotechnology company’s stock worth $119,363,000 after acquiring an additional 199,322 shares during the last quarter. Thrivent Financial for Lutherans raised its stake in Repligen by 6.1% in the 3rd quarter. Thrivent Financial for Lutherans now owns 638,602 shares of the biotechnology company’s stock valued at $95,037,000 after acquiring an additional 36,773 shares during the period. Finally, New York State Common Retirement Fund lifted its holdings in Repligen by 14.4% during the 3rd quarter. New York State Common Retirement Fund now owns 567,044 shares of the biotechnology company’s stock valued at $84,387,000 after purchasing an additional 71,274 shares during the last quarter. Institutional investors own 97.64% of the company’s stock.

Insider Activity at Repligen

In related news, Director Anthony Hunt sold 22,191 shares of the stock in a transaction on Tuesday, September 10th. The stock was sold at an average price of $145.37, for a total value of $3,225,905.67. Following the completion of the sale, the director now directly owns 139,840 shares in the company, valued at $20,328,540.80. This represents a 13.70 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 1.20% of the stock is currently owned by insiders.

Repligen Price Performance

Shares of NASDAQ:RGEN opened at $148.50 on Wednesday. The company has a current ratio of 10.44, a quick ratio of 8.76 and a debt-to-equity ratio of 0.26. The stock has a market capitalization of $8.32 billion, a PE ratio of -401.34, a PEG ratio of 4.53 and a beta of 0.96. The firm has a 50 day moving average of $141.29 and a 200-day moving average of $142.10. Repligen Co. has a 12 month low of $113.50 and a 12 month high of $211.13.

Repligen (NASDAQ:RGEN) last released its earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share for the quarter, topping the consensus estimate of $0.34 by $0.09. Repligen had a positive return on equity of 3.90% and a negative net margin of 3.36%. The firm had revenue of $154.87 million during the quarter, compared to analysts’ expectations of $153.34 million. During the same period in the prior year, the company earned $0.23 earnings per share. The company’s quarterly revenue was up 9.7% on a year-over-year basis. On average, equities research analysts predict that Repligen Co. will post 1.52 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages recently commented on RGEN. Wells Fargo & Company started coverage on shares of Repligen in a report on Tuesday, August 27th. They set an “overweight” rating and a $180.00 target price for the company. Wolfe Research initiated coverage on Repligen in a report on Thursday, November 14th. They set a “peer perform” rating for the company. Royal Bank of Canada reissued an “outperform” rating and set a $205.00 price target on shares of Repligen in a report on Thursday, September 26th. Finally, StockNews.com raised Repligen from a “sell” rating to a “hold” rating in a report on Friday, November 22nd. Four investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $190.25.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.